Blood And Tears in Alzheimer's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Neurodegenerative Diseases. Basic parameters: from 30 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Examination of Alzheimer's Disease Biomarkers in Tears and Dry Blood Spots
Overview
This study aims to investigate whether biomarkers of Alzheimer's disease can be found in tearfluid, as well as dried bloodspots in patients with Alzheimer's disease, other dementia diagnoses compared to controls.
Detailed description
Participants under investigation of a neurodegenerative disease who have a planned lumbar puncture in the Memory clinic will be invited to this study. On the same day of the lumbar puncture, tear fluid and dry blod spots will be collected.
Tear fluid is collected using Shirmer's test. Dried blood spots are obtained by a small prick in the finger with a lancet. The blood droplet is transferred onto a special piece of filter paper, where it dries.
As a sub-study, participants who have provided written consent specifically for this purpose will repeat the test with dried blood spots at home one week after participating in the study. The samples are submitted to the Memory Clinic at the participant's next scheduled appointment.
Tear fluid, dried blood spots, as well as blood and cerebrospinal fluid will be examined for AD-related pathology.
Primary outcome measures
- AD related biomarkers in tear fluid [Time frame: Two years]
- AD related biomarkers in dry blod spots [Time frame: Two years]
Secondary outcome measures (1)
- Testing dry blod spots at home [Time frame: Two years]
Eligibility criteria
Inclusion criteria
Inclusion criteria for patients:
- Lumbar puncture with CSF avaiable for analysis
- Diagnosis of Alzheimer's disease, Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) or Normal pressure hydrocephalus (NPH)
- Of legal age.
Inclusion criteria for controls:
- Lumbar puncture with CSF avaiable for analysis
- No neurological disease.
- Of legal age.
Exclusion criteria
- No lumbar puncture
- Clinically assessed as unfit to participate in the project.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Denmark · 1 center
- Danish Dementia Research Centre — Copenhagen
Identifiers
NCT: NCT06567431 · H-23078392